^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
GENE:

CTAG1A (Cancer/Testis Antigen 1A)

i
Other names: CTAG1A, Cancer/Testis Antigen 1A, LAGE2A, ESO1, Autoimmunogenic Cancer/Testis Antigen NY-ESO-1, Cancer/Testis Antigen 6.1, L Antigen Family Member 2, Cancer/Testis Antigen 1, LAGE-2, CT6.1, New York Esophageal Squamous Cell Carcinoma 1, Cancer/Testis Antigen 1-A, NY-ESO-1, CTAG1A, LAGE2B, CTAG1, LAGE2, CTAG
11ms
Cell death pathway regulation by fatty acid metabolism-related genes in neuroblastoma: a multi-omics analysis identifying CHD5 as a novel biomarker. (PubMed, Discov Oncol)
The developed fatty acid metabolism prognostic risk model underscores the significance of fatty acids in neuroblastoma prognosis and immune landscape, thereby facilitating the optimization of chemotherapy and immunotherapy strategies for this disease. The comprehensive analysis of cell death pathways revealed distinct regulatory mechanisms of signature genes, particularly highlighting TP63's central role in coordinating multiple cell death processes. CHD5, as an identified gene inhibiting the proliferation, invasion and metastasis of neuroblastoma cells, serves as a novel tumor biomarker.
Journal • IO biomarker
|
TP63 (Tumor protein 63) • CTAG1A (Cancer/Testis Antigen 1A)
1year
The value of serum tumor-associated autoantibodies in screening and diagnosis of gastric cancer. (PubMed, Clin Chim Acta)
The determination of serum autoantibody panel has clinical value in screening and prediction of gastric cancer, and can be used as an auxiliary index in clinical diagnosis. The combination of 7-TAAs and Helicobacter pylori can effectively improve the screening specificity and positive predictive value. The detection results of different proteins were related to the stage of disease, the degree of tumor differentiation and the depth of invasion.
Journal
|
CLDN18 (Claudin 18) • PBRM1 (Polybromo 1) • CTAG1A (Cancer/Testis Antigen 1A) • RASSF7 (Ras Association Domain Family Member 7)
over2years
Characterization of Cancer/Testis Antigens as Prognostic Markers of Ovarian Cancer. (PubMed, Diagnostics (Basel))
The CCT4 up-regulation and PRAME mutations were correlated with a good prognosis for ovarian cancer, while higher levels of GAGE2A and CT45A1 mRNAs were correlated with a poor prognosis for ovarian cancer patients. Thus, GAGE2, CT45, CCT4, and PRAME cancer/testis antigens can be considered as potential prognostic markers for ovarian tumors, and GAGE2, CCT4, and PRAME were revealed to be correlated with the prognosis for ovarian cancer patients for the first time.
Journal
|
CTAG1B (Cancer/testis antigen 1B) • MAGEA4 (Melanoma antigen family A, 4) • PRAME (Preferentially Expressed Antigen In Melanoma) • ACRBP (Acrosin Binding Protein) • CTAG1A (Cancer/Testis Antigen 1A) • MAGEC1 (MAGE Family Member C1) • KDM5B (Lysine Demethylase 5B) • MAGEA1 (MAGE Family Member A1)
|
CTAG1A expression
over2years
Comparative proteome and serum analysis identified FSCN1 as a marker of abiraterone resistance in castration-resistant prostate cancer. (PubMed, Prostate Cancer Prostatic Dis)
Our analysis identified baseline FSCN1 serum levels to be independently associated with poor survival of Abi-treated, but not Doc-treated mCRPC patients, suggesting a therapy specific prognostic value for FSCN1.
Journal
|
CTAG1A (Cancer/Testis Antigen 1A) • KLK2 (Kallikrein-related peptidase 2)
|
docetaxel • abiraterone acetate
over2years
Expression and Prognostic Significance of PD-L1 and NY-ESO1 in Gallbladder Carcinoma. (PubMed, In Vivo)
Patients whose gallbladder cancer expresses NY-ESO1 or PD-L1 might be candidates for immunotherapy.
Journal • PD(L)-1 Biomarker • IO biomarker
|
PD-L1 (Programmed death ligand 1) • PD-1 (Programmed cell death 1) • CTAG1B (Cancer/testis antigen 1B) • CTAG1A (Cancer/Testis Antigen 1A)
|
PD-L1 expression • CTAG1B expression
over3years
The Expression Patterns of Human Cancer-Testis Genes Are Induced through Epigenetic Drugs in Colon Cancer Cells. (PubMed, Pharmaceuticals (Basel))
These findings confirm that a subset of CT genes can be regulated by hypomethylating drugs and subsequently provide a potential therapeutic target for cancer.
Journal
|
CTAG1A (Cancer/Testis Antigen 1A) • NUTM1 (NUT Midline Carcinoma Family Member 1)
|
trichostatin A (VTR-297)
over3years
Multi-Omics Analysis of the Tumor Microenvironment in Liver Metastasis of Colorectal Cancer Identified FJX1 as a Novel Biomarker. (PubMed, Front Genet)
FJX1 is thought to affect chromogenic modification enzymes, the Notch signaling system, cell senescence, and other signaling pathways, according to KEGG enrichment analysis. FJX1 may be a critical target in colorectal cancer metastasis, and thus has the potential as a new biomarker to predict and treat colorectal cancer liver metastases.
Journal
|
CTAG1A (Cancer/Testis Antigen 1A)
over3years
Cancer-Testis Gene Biomarkers Discovered in Colon Cancer Patients. (PubMed, Genes (Basel))
TKTL2 expression was also observed in 50% of leukemia samples but not in the BC samples. More experiments at the protein level and with a larger cohort of patients are required to evaluate this finding.
Journal
|
CTAG1A (Cancer/Testis Antigen 1A)
4years
Integration of IgG and IgA Autoantibodies for Early Diagnosis of Hepatocellular Carcinoma. (PubMed, Clin Chim Acta)
Serum IgG autoantibodies against p53, CTAG1A and TIF1γ, and IgA autoantibody against TIF1γ present the diagnostic value for early HCC, of which anti-p53-IgG is a preferable biomarker. The panel comprised of four autoantibodies might contribute to early HCC diagnosis.
Retrospective data • Journal
|
CTAG1A (Cancer/Testis Antigen 1A)
almost5years
Analysis of LAGEs Family Gene Signature and Prognostic Relevance in Breast Cancer. (PubMed, Diagnostics (Basel))
Significant associations of LAGE family genes were correlated with the cell cycle, focal adhesion, and extracellular matrix (ECM) receptor interactions as indicated by functional enrichment analyses. Collectively, LAGE family members' gene expression levels were related to adverse clinicopathological factors and prognoses of BRCA patients; therefore, LAGEs have the potential to serve as prognosticators of BRCA patients.
Journal • Gene Signature • BRCA Biomarker
|
LAG3 (Lymphocyte Activating 3) • BRCA (Breast cancer early onset) • CTAG1B (Cancer/testis antigen 1B) • CTAG1A (Cancer/Testis Antigen 1A) • CTAG2 (Cancer/testis antigen 2)
|
LAG3 expression • LAG3 overexpression